John Crowley

Josh Schimmer × Sam Fazeli × Brian Skorney × Yaron Werber × John Crowley

BIO CEO John Crowley says rising US trial costs and regulatory uncertainty make capital flowing to China “perfectly rational.”His FDA prescription—stability, consistency, transparency, and modernization—puts “the next 6 months” in focus.MFN codification could be “devastating” and “unmanageable” before Section 232 action due by the last week of March, while ReGenix’s PLAG1 integration tests AAV safety.

Eric Schmidt × Sam Fazeli × Yaron Werber × John Crowley

Novo Nordisk’s 8–10% selloff after REDEFINE 2 may overemphasize CagriSema’s 12.6% placebo-adjusted loss, while dosing flexibility, tolerability and safety could shape commercial outcomes.Policy uncertainty around MFN, tariffs, vaccines and China, plus April 7 week proposals, March 28 BioNTech data and Legend’s capacity expansion, puts durable reform and execution in focus.

Daphne Zohar × John Maraganore × Mike Yee × Sam Fazeli × John Crowley

Biotech entered JPM at “five out of 10,” with macro steering capital and Metsera’s obesity IPO testing a discriminating window.J&J’s $14.6 billion Intra-Cellular Therapies acquisition—following $1.22 billion raised and approximately 13× value creation—shows pharma’s appetite for derisked CNS assets, while China’s speed and cost make FDA trial reform a potential catalyst.